natgillin/translations-raw huggingface dataset:
Frequency not known (cannot be estimated from the available data) Skin changes where you use the injection (lipodystrophy): It is not known if Ryzodeg may cause lipodystrophy but such skin changes have been seen with other types of insulin.
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) Spremembe kože na mestu injiciranja (lipodistrofija): Ni znano, ali zdravilo Ryzodeg povzroči lipodistrofijo, vendar so takšne spremembe opažali pri drugih vrstah insulina.
• The best places to inject are the front of your waist (abdomen), upper arms or the front of your thighs.
• Najprimernejša mesta za injiciranje so sprednji del pasu (trebuh), nadlahti ali sprednji del stegen.
Hypoglycaemia (too low blood sugar) may occur very commonly with insulin treatment (may affect more than 1 in 10 people).
Hipoglikemija (prenizek krvni sladkor) je zelo pogost neželeni učinek pri zdravljenju z insulinom (pojavi se lahko pri več kot 1 od 10 bolnikov).
• you find it hard to recognise too low blood sugar.
• težko prepoznate znake prenizkega krvnega sladkorja.
Hypoglycaemia Rate (per patient year of exposure) Severe
Delež hipoglikemij (na bolnik-let izpostavljenosti) Hude
• Insert the needle into your skin as your doctor or nurse has shown you.
• Zabodite iglo v kožo, kot sta vam pokazala zdravnik ali medicinska sestra.
If you stop using Ryzodeg
Če ste prenehali uporabljati zdravilo Ryzodeg
IDegAsp 0.8 U/kg
Zdravljenje IDegAsp 0,8 e./kg
At baseline, HbA1c was 8.4% in both treatment groups and after 2 years HbA1c was 7.5% both with insulin degludec and insulin glargine.
HbA1c je bila v obeh podskupinah 8,4%, po 2 letih pa je bil HbA1c 7,5% tako pri skupini, ki je prejemala insulin degludek, kot tisti, ki je prejemala insulin glargin.
The cardiovascular safety of insulin degludec as compared to insulin glargine was confirmed (HR 0.91 [0.78; 1.06]) (Figure 2).
Varnost insulina degludek glede pojava srčno-žilnih dogodkov v primerjavi z insulinom glargin je bila potrjena (razmerje ogroženosti 0,91 [0,78; 1,06]) (Slika 2).
Ryzodeg can be used in elderly, but you may need to check your blood sugar level more often.
Zdravilo Ryzodeg se lahko uporablja pri starostnikih, a si morate krvni sladkor kontrolirati pogosteje.
This effect is maintained in the co-formulation with insulin aspart and does not interfere with the rapid-acting insulin aspart monomers.
Ta učinek se v skupnem pripravku z insulinom aspart ohrani in ne ovira monomerov hitrodelujočega insulina aspart.
The pharmacokinetic profile for insulin aspart appears 14 minutes after injection with a peak concentration after 72 minutes.
Za farmakokinetični profil insulina aspart je značilno, da se insulin pojavi v plazmi 14 minut po injiciranju, največjo koncentracijo pa doseže po 72 minutah.
Local reactions: Local reactions at the place you inject yourself may occur.
Lokalne reakcije: na mestu injiciranja se lahko pojavijo lokalne reakcije.
As with other basal insulin products or insulin products with a basal component, the prolonged effect of Ryzodeg may delay recovery from hypoglycaemia.
Kot velja za druga bazalna insulinska zdravila ali insuline z bazalno sestavino, lahko podaljšani učinek zdravila Ryzodeg upočasni okrevanje po hipoglikemiji.
• Rapid-acting insulin called insulin aspart, this lowers your blood sugar soon after you inject it.
• hitrodelujoči insulin, ki se imenuje insulin aspart - zniža krvni sladkor kmalu po injiciranju.
The pharmacodynamic effect of Ryzodeg is distinctively separated for the two components (Figure 1), and the resulting action profile reflects the individual components, the rapid-acting insulin aspart and the basal component insulin degludec.
Farmakodinamični učinek zdravila Ryzodeg je za obe sestavini jasno ločen (slika 1); njegov profil delovanja odraža obe sestavini, hitrodelujoči insulin aspart in bazalno sestavino insulin degludek.
In children, extra care should be taken to match insulin doses with food intake and physical activities in order to minimise the risk of hypoglycaemia.
Pri otrocih je še posebej treba paziti, da odmerki insulina ustrezajo vnosu hrane in telesni aktivnosti, da se zmanjša tveganje za hipoglikemijo.
Ryzodeg has been administered to children and adolescents up to 18 years of age for the investigation of pharmacokinetic properties (see section 5.2).
Otroci in mladostniki do 18. leta starosti so zdravilo Ryzodeg dobivali za preučitev farmakokinetičnih lastnosti (glejte poglavje 5.2).
When using Ryzodeg once-daily, changing to twice daily should be considered when higher doses are needed, e.g. to avoid hypoglycaemia.
Če se zdravilo Ryzodeg uporablja enkrat na dan, je, v primeru potrebe po uporabi višjih odmerkov, treba razmisliti o prehodu na odmerjanje dvakrat na dan, npr. da se izognemo pojavu hipoglikemije.
It demonstrates superior improvements in fasting plasma glucose levels compared to patients treated with BIAsp 30.
Izboljšanje koncentracije glukoze v plazmi na tešče je z zdravilom Ryzodeg boljše kot pri bolnikih, zdravljenih z BIAsp 30.
Ryzodeg is to be dosed in accordance with the individual patient's needs.
Zdravilo Ryzodeg je treba odmerjati glede na potrebe posameznega bolnika.
• Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting (see section 4).
• Mesto injiciranja na posameznem delu telesa, kamor si injicirate zdravilo, menjajte vsak dan, da zmanjšate verjetnost za nastanek zatrdlin in ugreznjenosti kože (glejte poglavje 4).
Pregnancy There is no clinical experience with the use of this medicinal product in pregnant women.
Kliničnih izkušenj z uporabo tega zdravila pri nosečnicah ni.
Dose-adjustments are recommended to be based on fasting plasma glucose measurements.
Prilagajanje odmerka je priporočljivo opreti predvsem na meritve koncentracije glukoze v plazmi na tešče.
• To see precisely how much insulin is left, use the dose counter:
• Če želite videti, koliko je še insulina, uporabite števec odmerka:
• Always carry an extra pen and new needles with you, in case of loss or damage.
• Vedno imejte pri sebi rezervni injekcijski peresnik in nove igle, če jih izgubite ali se poškodujejo.
• angiotensin converting enzyme (ACE) inhibitors, for some heart problems or high blood pressure.
• zaviralce angiotenzinske konvertaze (zaviralce ACE (angiotensin converting enzyme)) (uporabljajo se za zdravljenje določenih bolezni srca ali visokega krvnega tlaka).
1 Once-daily regimen + Metformin
1 Shema enkrat na dan + metformin
Ryzodeg must not be added to infusion fluids.
Zdravila Ryzodeg se ne sme dodajati infuzijskim tekočinam.
DEVOTE was a randomised, double-blind, and event-driven clinical trial focusing on insulin degludec, the long-acting component of Ryzodeg.
DEVOTE je bilo randomizirano, dvojno slepo in s številom dogodkov omejeno klinično preskušanje, osredotočeno na insulin degludek, ki je dolgodelujoča komponenta zdravila Ryzodeg.
SC use
za s.c. uporabo
Patients should not take an extra dose to make up for a missed dose.
Bolnik ne sme vzeti dodatnega odmerka, da bi nadomestil pozabljenega.
Ryzodeg cartridge 100
Ryzodeg peresnik 100
Pack sizes of 5 and 10 cartridges of 3 mL.
Pakiranja s 5 in 10 vložki po 3 ml.
Split the dose based on individual patient's needs and administer with main meals.
Odmerek je treba razdeliti glede na potrebe posameznega bolnika, bolnik pa ga naj uporablja z glavnima obrokoma.
Ryzodeg can be used in renal and hepatic impaired patients.
Zdravilo Ryzodeg se lahko uporablja pri bolnikih z ledvično in jetrno okvaro.
In all trials in type 2 diabetes mellitus, oral antidiabetic drugs (OADs) were allowed.
V vseh preskušanjih pri sladkorni bolezni tipa 2 je bila dovoljena uporaba peroralnih antidiabetikov (POAD).
Degradation of insulin degludec and insulin aspart is similar to that of human insulin; all metabolites formed are inactive.
Razgradnja insulina degludek in insulina aspart je podobna razgradnji človeškega insulina; vsi nastali presnovki so neaktivni.
The recommended starting dose of Ryzodeg is 60-70% of the total daily insulin requirements in combination with short-/rapid-acting insulin at the remaining meals followed by individual dosage adjustments.
Priporočeni začetni odmerek zdravila Ryzodeg obsega 60-70 % celotne dnevne potrebe po insulinu v kombinaciji s kratko-/hitrodelujočim insulinom, ki se uporablja ob preostalih obrokih, čemur sledi individualna prilagoditev odmerka.
Ryzodeg causes a lower rate of overall and nocturnal hypoglycaemia (Table 2).
Zdravilo Ryzodeg povzroča manj vseh hipoglikemij in nočnih hipoglikemij (preglednica 2).
You can carry your Ryzodeg cartridge (Penfill) with you and keep it at room temperature (not above 30°C) for up to 4 weeks.
Vložek Ryzodeg Penfill lahko nosite s seboj in shranjujete na sobni temperaturi (do 30 °C) do 4 tedne.
Substances added to Ryzodeg may cause degradation of insulin degludec and/or insulin aspart.
Dodajanje snovi zdravilu Ryzodeg bi lahko povzročilo razgradnjo insulina degludek in/ali insulina aspart.
If you have kidney or liver problems, you may need to check your blood sugar level more often.
Če imate težave z ledvicami ali jetri Če imate težave z ledvicami ali jetri, si morate krvni sladkor kontrolirati pogosteje.
It is not known if Ryzodeg affects the baby in pregnancy or during breast-feeding.
Ni znano, ali zdravilo Ryzodeg vpliva na otroka med nosečnostjo ali dojenjem.
Before you use Ryzodeg for the first time, your doctor or nurse will show you how to use it.
Pred prvo uporabo zdravila Ryzodeg vam bosta zdravnik ali medicinska sestra pokazala, kako se ga uporablja.
Ryzodeg can be used in the elderly.
Zdravilo Ryzodeg se lahko uporablja pri starostnikih.
Important information about some of the ingredients in Ryzodeg
Pomembne informacije o nekaterih sestavinah zdravila Ryzodeg
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Ryzodeg and other insulin products.
Bolnike je treba opozoriti, da pred injiciranjem vedno preverijo nalepko insulina, da po pomoti ne zamenjajo zdravila Ryzodeg in drugih insulinskih zdravil.
This assessment supports the use of Ryzodeg in adolescent patients with type 2 diabetes mellitus.
Ocena podpira uporabo zdravila Ryzodeg pri mladostnikih s sladkorno boleznijo tipa 2.
• Unscrew the needle and dispose of it carefully.
• Odvijte iglo in jo pazljivo zavrzite.
After subcutaneous injection, soluble and stable multi-hexamers of insulin degludec are formed creating a depot of insulin in the subcutaneous tissue, while not interfering with the rapid release of insulin aspart monomers into the circulation.
Absorpcija Po subkutani injekciji se tvorijo topni in stabilni multiheksameri insulina degludek in s tem ustvarijo depo insulina v podkožnem tkivu, hkrati pa ne ovirajo hitrega sproščanja monomerov insulina aspart v obtok.
Do not use Ryzodeg
Ne uporabljajte zdravila Ryzodeg:
They may make it harder to recognise the warning signs of too low blood sugar (see section 4 ‘Warning signs of too low blood sugar')
Zaradi teh zdravil bo morda težje prepoznati opozorilne znake prenizkega krvnega sladkorja (glejte poglavje 4, podpoglavje »Opozorilni znaki prenizkega krvnega sladkorja«);
It is unknown whether insulin degludec/insulin aspart is excreted in human milk.
Ni znano, ali se insulin degludek in insulin aspart izločata v materino mleko.
The rapid absorption characteristics of the well-established insulin aspart are maintained by Ryzodeg.
Hitra absorpcija dobro poznanega insulina aspart je v zdravilu Ryzodeg ohranjena.
Steady-state serum concentration of the basal component (insulin degludec) is reached after 2-3 days of daily Ryzodeg administration.
Serumska koncentracija v stanju dinamičnega ravnovesja bazalne sestavine (insulina degludek) je dosežena po 2 do 3 dneh vsakodnevne uporabe zdravila
Steady state will occur after 2-3 days of dose administration.
Stanje dinamičnega ravnovesja je doseženo po 2 do 3 dneh uporabe.
EU/1/12/806/001 1 pen of 3 mL EU/1/12/806/002 1 pen of 3 mL and 7 NovoFine needles EU/1/12/806/003 1 pen of 3 mL and 7 NovoTwist needles EU/1/12/806/004 5 pens of 3 mL
EU/1/12/806/001 1 injekcijski peresnik po 3 ml EU/1/12/806/002 1 injekcijski peresnik po 3 ml in 7 igel NovoFine EU/1/12/806/003 1 injekcijski peresnik po 3 ml in 7 igel NovoTwist EU/1/12/806/004 5 injekcijskih peresnikov po 3 ml
• if the cartridge is damaged or has not been stored correctly (see section 5 ‘How to store
• če je injekcijski peresnik poškodovan ali ni bil pravilno shranjen (glejte poglavje 5
eat more or exercise less than usual; drink alcohol; get an infection or a fever; have not used enough insulin; keep using less insulin than you need; forget to use your insulin or stop using insulin without talking to your doctor.
Previsok krvni sladkor se vam lahko pojavi, če: jeste več kot ponavadi ali ste manj telesno dejavni kot ponavadi, pijete alkohol, imate okužbo ali zvišano telesno temperaturo, uporabite premalo insulina, večkrat zapored uporabite manj insulina, kot ga potrebujete, pozabite ali prenehate uporabljati insulin, ne da bi se prej posvetovali z zdravnikom.
Ryzodeg (o.d.)1
Ryzodeg (1x/dan)1
If you forget a dose, inject the missed dose with your next large meal on that day and thereafter resume your usual dosing schedule.
Če pozabite odmerek, si injicirajte pozabljeni odmerek ob naslednjem obilnem obroku dneva in potem nadaljujte s predpisanim odmerjanjem.
• Basal insulin called insulin degludec, this has a long blood sugar-lowering effect.
• bazalni insulin, ki se imenuje insulin degludek - dolgotrajno znižuje krvni sladkor,
When changing from another insulin regimen to Ryzodeg, dose reduction of total insulin needs to be considered on an individual basis in order to minimise the risk of hypoglycaemia (see section 4.4).
Pri zamenjavi insulina z zdravilom Ryzodeg je pri vsakem bolniku posebej treba presoditi o zmanjšanju celokupnega odmerka insulina, da se zmanjša tveganje za pojav hipoglikemije (glejte poglavje 4.4).
An efficacy and safety evaluation for adolescent patients with type 2 diabetes mellitus has been made using data from adolescent and adult patients with type 1 diabetes mellitus and adult patients with type 2 diabetes mellitus.
Korist in varnost zdravila pri mladostnikih s sladkorno boleznijo tipa 2 so ocenili s pomočjo podatkov, pridobljenih pri mladostnikih in odraslih s sladkorno boleznijo tipa 1 ter odraslih bolnikih s sladkorno boleznijo tipa 2.
Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Zdravljenje sladkorne bolezni pri odraslih, mladostnikih in otrocih, starih 2 leti in več.
The trial had a median duration of 2 years and compared the cardiovascular safety of insulin degludec vs insulin glargine (100 units/mL) in 7,637 patients with type 2 diabetes mellitus at high risk of cardiovascular events.
V preskušanju z medianim trajanjem 2 leti so primerjali insulin degludek in insulin glargin (100 enot/ml) glede varnosti za pojav srčno-žilnih dogodkov pri 7637 bolnikih s sladkorno boleznijo tipa 2 in z velikim tveganjem za srčno-žilne dogodke.
Ryzodeg 100 units/mL solution for injection in pre-filled pen EU/1/12/806/001
Ryzodeg 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku EU/1/12/806/001
The pre-filled pen can provide a dose of 1-80 units in one injection in steps of 1 unit.
Napolnjen injekcijski peresnik lahko injicira 1-80 enot v eni injekciji, v korakih po 1 enoto.
What Ryzodeg looks like and contents of the pack
Izgled zdravila Ryzodeg in vsebina pakiranja
• Too low blood sugar (hypoglycaemia)
• Prenizek krvni sladkor (hipoglikemija)
Total exposure of insulin degludec after single dose administration was, however, higher in children and adolescents than in adults with type 1 diabetes mellitus.
Celotna izpostavljenost insulinu degludek po enkratnem odmerku pa je pri otrocih in mladostnikih večja kot pri odraslih s sladkorno boleznijo tipa 1.
Ryzodeg can be used in adolescents and children from the age of 2 years with diabetes mellitus.
Zdravilo Ryzodeg se lahko uporablja pri mladostnikih in otrocih, starejših od 2 let, s sladkorno boleznijo.
• The active substances are insulin degludec and insulin aspart.
• Učinkovini sta insulin degludek in insulin aspart.
The recommended total daily starting dose is 10 units with meal(s) followed by individual dosage adjustments.
Priporočeni začetni skupni dnevni odmerek je 10 enot ob obrokih, čemur sledi prilagoditev odmerjanja posamezniku.
Before you use Ryzodeg for the first time, your doctor or nurse will show you how to use the pre-filled pen.
Pred prvo uporabo zdravila Ryzodeg vam bosta zdravnik ali medicinska sestra pokazala, kako se uporablja napolnjen injekcijski peresnik.
The pharmacokinetic properties of Ryzodeg in type 1 diabetes mellitus were investigated in children (6-11 years) and adolescents (12-18 years) and compared to adults after single dose administration.
Farmakokinetične lastnosti zdravila Ryzodeg pri zdravljenju sladkorne bolezni tipa 1 so raziskali pri otrocih (od 6. do 11. leta) in mladostnikih (od 12. do 18. leta) in jih primerjali s tistimi pri odraslih po aplikaciji enega odmerka.
Ryzodeg 100 units/mL solution for injection in pre-filled pen After first opening or carried as a spare, the medicinal product may be stored for a maximum of 4 weeks.
Ryzodeg 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku Po prvem odprtju ali ko se uporablja kot rezerva, se lahko zdravilo shranjuje največ 4 tedne.
The rates (events per patient-year of exposure) of confirmed hypoglycaemia (ISPAD 2009 definition: 46.23 vs 49.55) and nocturnal confirmed hypoglycaemia (5.77 vs 5.40) were comparable with Ryzodeg vs insulin detemir whereas the rate of severe hypoglycaemia (0.26 vs 0.07) was higher in the Ryzodeg arm although the difference was not statistically significant.
46,23 v primerjavi z 49,55) in potrjene nočne hipoglikemije (5,77 v primerjavi s 5,40) so bili pri zdravilu Ryzodeg primerljivi z deleži pri insulinu detemir, delež hude hipoglikemije pa je bil v skupini z zdravilom Ryzodeg večji (0,26 v primerjavi z 0,07), čeprav razlika ni bila statistično značilna.
Detailed instructions accompanying the pre-filled pen must be followed.
Upoštevati je treba podrobno navodilo, priloženo napolnjenemu injekcijskemu peresniku.
• The other ingredients are glycerol, metacresol, phenol, sodium chloride, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections (see section 2).
• Druge sestavine zdravila so glicerol, metakrezol, fenol, natrijev klorid, cinkov acetat, klorovodikova kislina in natrijev hidroksid (za uravnavanje pH) in voda za injekcije (glejte poglavje 2).
The steady-state pharmacokinetic properties of the insulin degludec component of Ryzodeg were investigated using a population pharmacokinetic analysis in children down to 1 year of age.
Farmakokinetične lastnosti insulina degludek, sestavine zdravila Ryzodeg, v stanju dinamičnega ravnovesja so na osnovi analize populacijske farmakokinetike raziskali pri otrocih, starejših od 1 leta.
The efficacy and safety of Ryzodeg have been studied in a randomised controlled clinical trial in children and adolescents with diabetes mellitus type 1 for a period of 16 weeks (n=362).
Učinkovitost in varnost uporabe zdravila Ryzodeg so raziskovali v randomiziranem nadzorovanem kliničnem preskušanju pri otrocih in mladostnikih s sladkorno boleznijo tipa 1 v obdobju 16 tednov
This medicinal product is to be used once daily at mealtime in combination with short-/rapid-acting insulin at the remaining meals followed by individual dosage adjustments.
To zdravilo je treba uporabljati enkrat dnevno ob obroku, v kombinaciji s kratko-/hitrodelujočim insulinom ob preostalih obrokih; slediti mora individualna prilagoditev odmerka.
The pharmacokinetic properties of insulin degludec in children (1-11 years) and adolescents (1218 years) were at steady state comparable to those observed in adults with type 1 diabetes mellitus.
Farmakokinetične lastnosti insulina degludek pri otrocih (od 1. do 11. leta) in mladostnikih (od 12. do 18. leta) so v stanju dinamičnega ravnovesja primerljive s tistimi pri odraslih s sladkorno boleznijo tipa 1.
You can carry your Ryzodeg pre-filled pen (FlexTouch) with you and keep it at room temperature (not above 30°C) or in a refrigerator (2°C to 8°C) for up to 4 weeks.
Napolnjen injekcijski peresnik Ryzodeg FlexTouch lahko nosite s seboj in shranjujete na sobni temperaturi (do 30 °C) ali v hladilniku (2 °C - 8 °C) do 4 tedne.
Having too low or too high blood sugar can affect your ability to drive or use any tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Če imate prenizek ali previsok krvni sladkor, lahko to vpliva na vašo sposobnost za upravljanje vozil ter uporabo orodij in strojev.
Do not use this medicine after the expiry date which is stated on the Penfill label and carton, after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki vložka Penfill in škatli, poleg oznake »Uporabno do«.
The ratio of mitogenic relative to metabolic potency for insulin degludec is comparable to that of human insulin.
Razmerje mitogene moči v primerjavi s presnovno močjo je pri insulinu degludek podobno kot pri človeškem insulinu.
If a dose of this medicinal product is missed, the patient can take the missed dose with the next main meal of that day and thereafter resume the usual dosing schedule.
Če bolnik izpusti odmerek tega zdravila, si lahko izpuščeni odmerek aplicira ob naslednjem glavnem obroku istega dneva in nato nadaljuje predpisano odmerjanje.
1 Twice-daily regimen ± metformin ± pioglitazone ± DPP-4 inhibitor 2 Twice-daily regimen ± metformin
1 Shema dvakrat na dan ± metformin ± pioglitazon ± zaviralec DPP-4
• Ensuring you use the right type of insulin - always check the insulin label before each injection to avoid accidentally confusing Ryzodeg with other insulin products.
• uporabo pravega insulina; pred injiciranjem vedno preverite nalepko insulina, da po pomoti ne zamenjate zdravila Ryzodeg in drugih insulinskih zdravil.
Prandial Blood glucose Increment 90 minutes after dosing meal (Plasma) (mmol/L)
Prandialni porast glukoze v krvi 90 minut po obroku z aplikacijo zdravila (plazma) (mmol/l) Na koncu preskušanja
At week 16, the mean total daily insulin dose was 0.88 vs 1.01 units/kg in the Ryzodeg and insulin detemir arms, respectively.
V 16. tednu je bil celoten povprečni dnevni odmerek insulina v skupini z zdravilom Ryzodeg 0,88 enot/kg, v skupini z insulinom detemir pa 1,01 enot/kg.
This medicinal product is a soluble insulin product consisting of the basal insulin degludec and the rapid-acting prandial insulin aspart.
To zdravilo je topno insulinsko zdravilo, sestavljeno iz bazalnega insulina degludek in hitrodelujočega prandialnega insulina aspart.
Patients with type 2 diabetes mellitus Ryzodeg can be administered once or twice daily with the main meal(s) alone, in combination with oral antidiabetic medicinal products, and in combination with bolus insulin (see section 5.1).
Zdravilo Ryzodeg se lahko uporablja enkrat ali dvakrat na dan z glavnim obrokom (glavnima obrokoma), in sicer sámo, v kombinaciji s peroralnimi antidiabetiki in v kombinaciji z bolusnim insulinom (glejte poglavje 5.1).
With Ryzodeg, hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria were reported rarely.
Pri zdravilu Ryzodeg so o preobčutljivosti (ki se kaže v obliki otekanja jezika in ustnic, driske, navzeje, utrujenosti in srbenja) in urtikariji poročali redko.
Based on results from clinical trials, the frequency, type and severity of adverse reactions observed in the elderly and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.
Pogostnost, vrsta in izrazitost neželenih učinkov, opaženih pri starostnikih in bolnikih z okvaro ledvic ali jeter na podlagi kliničnih izkušenj ne kažejo razlik v primerjavi s širšimi izkušnjami v splošni populaciji.